Q1 Earnings Estimate for Evotec Issued By HC Wainwright

Evotec SE (NASDAQ:EVO) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Evotec in a research note issued to investors on Thursday, November 7th. HC Wainwright analyst D. Tsao anticipates that the company will earn ($0.01) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Evotec’s current full-year earnings is ($0.51) per share. HC Wainwright also issued estimates for Evotec’s Q2 2025 earnings at $0.01 EPS, Q3 2025 earnings at $0.02 EPS, Q4 2025 earnings at $0.02 EPS and FY2025 earnings at $0.02 EPS.

EVO has been the subject of several other research reports. Jefferies Financial Group downgraded shares of Evotec from a “buy” rating to a “hold” rating and reduced their price objective for the stock from $8.70 to $3.80 in a research report on Monday, October 7th. Morgan Stanley downgraded shares of Evotec from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $15.00 to $6.00 in a research note on Monday, July 29th. Finally, Deutsche Bank Aktiengesellschaft lowered Evotec from a “hold” rating to a “sell” rating in a report on Thursday, August 8th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $5.93.

Evotec Price Performance

Shares of EVO opened at $4.13 on Friday. Evotec has a 52-week low of $2.85 and a 52-week high of $12.00. The company has a quick ratio of 1.73, a current ratio of 1.83 and a debt-to-equity ratio of 0.42. The stock has a 50 day moving average price of $3.51 and a 200 day moving average price of $4.21.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. Clear Harbor Asset Management LLC acquired a new position in Evotec in the 3rd quarter valued at about $104,000. Mediolanum International Funds Ltd acquired a new stake in shares of Evotec during the third quarter worth $512,000. Novo Holdings A S purchased a new position in Evotec in the 2nd quarter valued at $71,183,000. DCF Advisers LLC grew its position in Evotec by 140.5% in the 2nd quarter. DCF Advisers LLC now owns 114,953 shares of the company’s stock valued at $552,000 after buying an additional 67,156 shares during the last quarter. Finally, Vanguard Personalized Indexing Management LLC purchased a new position in Evotec during the 2nd quarter worth $87,000. 5.81% of the stock is currently owned by institutional investors and hedge funds.

About Evotec

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women’s health.